Clinical trials: Botulinum toxin type A
Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement…
- Trial name
- NCT02450526
- Testing
- Botulinum toxin type A
- Where
- 10 sites in China
- Volunteers
- 520 people
- Sponsor
- Ipsen
Crow's Feet Lines
MEDITOXIN® in Treatment of Crow's Feet Line
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
- Trial name
- NCT03317574
- Testing
- botulinum toxin type A
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Medy-Tox
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603615
- Testing
- Botulinum Toxin Type A
- Where
- 48 sites in United States, Canada and 7 more
- Volunteers
- 220 people
- Sponsor
- Allergan
Chronic Plantar Fasciitis
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
- Trial name
- NCT00447876
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Ipsen
Lateral Canthus Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).
- Trial name
- NCT01797081
- Testing
- botulinum toxin Type A (24 U), botulinum toxin Type A (12 U), Normal Saline
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Allergan
Muscle Spasticity
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity
- Trial name
- NCT03289702
- Testing
- CORETOX®, BOTOX®
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT04281745
- Testing
- CORETOX Inj
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Post-stroke Upper Limb Spasticity
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin.
- Trial name
- NCT00432666
- Testing
- IncobotulinumtoxinA (Xeomin)
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 148 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Facial Rhytides
An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A
This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.
- Trial name
- NCT01608659
- Testing
- botulinum toxin Type A
- Where
- Argentina
- Volunteers
- 110 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Blepharospasm, Hemifacial Spasm
Post Marketing Surveillance Study of Dysport
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
- Conditions
- Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis
- Trial name
- NCT00210431
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 783 people
- Sponsor
- Ipsen
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle…
- Trial name
- NCT01905683
- Testing
- IncobotulinumtoxinA (16-20 Units per kg body weight)
- Where
- 43 sites in Austria, Czechia and 10 more
- Volunteers
- 370 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Lines
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines
- Trial name
- NCT05804656
- Testing
- CKDB-501A, Botox®
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- CKD Bio Corporation
Essential Blepharospasm
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm
To compare the efficacy and safety of Hugel-Tox (Botulinum toxin A, Hugel, Korea) against Botox in the treatment of Essential Blepharospasm and to get a regulatory approval from KFDA
- Trial name
- NCT01791881
- Testing
- Hugeltox, Botulinum Toxin Type A(Botox®)
- Where
- 9 sites in South Korea
- Volunteers
- 172 people
- Sponsor
- Hugel
Migraine
Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis
The purpose of this study is to evaluate the efficacy of botulinum toxin type A (Dysport®) injections into pericranial muscles compared to placebo to prevent migraine attacks.
- Trial name
- NCT00301665
- Testing
- Botulinum toxin type A
- Where
- 9 sites in Czechia, Poland and 1 more
- Volunteers
- 138 people
- Sponsor
- Ipsen
Upper Limb Injury
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability…
- Trial name
- CARBUR (NCT06245772)
- Where
- 27 sites in France
- Volunteers
- 113 people
- Sponsor
- Ipsen
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Urinary Bladder, Overactive
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice.
- Trial name
- NCT02557971
- Testing
- onabotulinumtoxinA
- Where
- 7 sites in United States
- Volunteers
- 315 people
- Sponsor
- Allergan